Press Release

28 September 2023

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, September 28, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.
26 September 2023

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.
22 August 2023

Infographic | HitGen FY2023 Half-Year Report
10 August 2023

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

CHENGDU, China, August 10, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.
26 June 2023

HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research

CHENGDU, China, June 26, 2023 – HitGen Inc. ("HitGen", SSE: 688222.SH) has recently launched a newly upgraded version of its OpenDEL™ product, a self-service screening kit for novel molecules.
18 May 2023

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways. HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also support ARase programs from hit-to-lead chemistry to pre-clinical development.
28 April 2023

Infographic | HitGen FY2022 Annual Report

Infographic | HitGen FY2022 Annual Report
12 December 2022

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, December 12, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. (“Nitrase”), a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.
14 November 2022

Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, November 14, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE:688222.SH) today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd (“Daewoong”), a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients' lives. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
28 October 2022

Infographic | HitGen FY2022 Q3 Report

Infographic | HitGen FY2022 Q3 Report

News

Press Release

Thanks for reading!